TransMedics Group saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 90 to 93.
Here Are 3 Keys For Successful Stock Investing
IBD's unique rating tracks price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the best stocks tend to have an RS Rating of above 80 as they begin their largest price moves.
The IBD 50 stock has climbed more than 5% past a 92.63 entry in a first-stage cup without handle, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
Earnings growth picked up last quarter from 58% to 100%. But revenue gains fell from 50% to 48%.
TransMedics Group holds the No. 5 rank among its peers in the Medical-Products industry group. Penumbra is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
